Second-Line Treatment for Diabetic Gastroparesis When Prokinetics Are Contraindicated

Antiemetic Therapy as Primary Second-Line Treatment

The American Gastroenterological Association recommends antiemetic therapy with 5-HT3 receptor antagonists, such as ondansetron (4-8 mg twice or three times daily) or granisetron (1 mg twice daily or 34.3 mg patch weekly), as the primary second-line pharmacologic approach for diabetic gastroparesis when prokinetics are contraindicated 1, 2
Transdermal granisetron (3.1 mg/24 hours) has demonstrated efficacy in decreasing symptom scores by 50% in patients with refractory gastroparesis symptoms 2
The selection of 5-HT3 receptor antagonists depends on price, availability, and preferred mode of delivery, with ondansetron available in parenteral and enteral forms, and granisetron available as a liquid, tablets, and transdermal patch 2

The American Gastroenterological Association suggests that tricyclic antidepressants, such as amitriptyline (25-100 mg/day) or nortriptyline (25-100 mg/day), can reduce visceral pain perception through multiple mechanisms at different levels of the brain-gut axis 1, 2
Secondary amines, such as desipramine (25-75 mg/day) or nortriptyline (25-100 mg/day), have fewer side effects than tertiary amines, such as amitriptyline, with less sedation 1
Duloxetine (60-120 mg/day) can be used for visceral pain management, and gabapentin (>1200 mg/day in divided doses) or pregabalin (100-300 mg/day in divided doses) are anticonvulsant options for pain control 1

The American Gastroenterological Association recommends considering endoscopic injection of botulinum toxin A into the pyloric sphincter, gastric per-oral endoscopic myotomy (G-POEM), or gastric electrical stimulation for refractory symptoms 1
Jejunostomy tube feeding should be considered for patients unable to maintain adequate oral intake, defined as below 50-60% of energy requirements for more than 10 days 1

The American Gastroenterological Association advises against using medications that worsen gastroparesis, including opioids and GLP-1 agonists, which can significantly exacerbate symptoms 1
Synthetic cannabinoids, such as dronabinol or nabilone, have the potential to slow gastric emptying despite approval for chemotherapy-related nausea, and scopolamine (1.5 mg patch every 3 days) may paradoxically worsen symptoms through anticholinergic effects 1